spacer
home > pmps > winter 2020 > counteracting the effects of an opioid overdose
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Counteracting the Effects of an Opioid Overdose





Respiratory depression can occur from accidental and/or intentional overdose of opioid type substances. The neurochemical process, by which the opioid substance binds with opioid receptors in the brain stem and then desensitises the level of carbon dioxide in the blood stream, fails to activate the breathing mechanisms, leading to respiratory failure and death (1). The overdose process can be interrupted and reversed with the administration of an opioid antagonist, such as naloxone, thereby blocking the effects of the ingested opioids.

In 1971, the FDA approved naloxone, the opioid antagonist, reversal medication for public use. This life-saving medication was initially labeled for intravenous, intramuscular, or subcutaneous use. For nearly 50 years, naloxone has been used by emergency medical personnel to counteract the effects of opioid overdoses (1). According to the Centers for Disease Control and Prevention, the administration of naloxone from the years 1996 to 2014 assisted in reversing the effects of opioid overdoses in an estimated 26,000 opioid users (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Dr Todd Pizitz is a licensed clinical and forensic psychologist in private practice in Vista, California. As a forensic psychologist, Todd works with those afflicted with various types of addiction. For the past 17 years, he has worked closely with private and public defense attorneys, family court services, the District Attorney’s Office, county adult and juvenile probation, drug court, and federal probation. Todd routinely conducts psychological evaluations on those involved in the legal system.

Donald R Mealing is a Business Entrepreneur with more than 25 years’ experience as a CEO over a variety of successful businesses. Don has served on numerous Boards, including 14 years on the Board of Regents, Harris Manchester College, Oxford University, UK. He was Founder and CEO of American Corrective Counseling Services, one of the largest private counselling diversion companies servicing courts and prosecutors across the US criminal justice system. Don has lost three close relatives to opioid overdose.
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>

White Papers

ConsulTech GmbH

ConsulTech GmbH

ConsulTech is a consulting company founded in 1992. Since then, we have been supporting biotech-nology, pharmaceutical and medical technology companies as well as research institutions with the entire process of setting-up and executing proposals for R&D projects. In projects funded by the European Commission, ConsulTech supports the coordinator by resuming administrative tasks allow-ing coordinators and partners to fully concentrate on the scientific and technical success of the pro-ject. We solve financial and administrative issues, organise meetings, take care of the timely delivery of milestones and reports and much more.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement